UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/966,893	09/28/2001	Alessandra D'Azzo	SJ-01-0020	4347

28258   7590   03/28/2007
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
OFFICE OF TECHNOLOGY LICENSING
332 N. LAUDERDALE
MEMPHIS, TN 38105

EXAMINER
FRONDA, CHRISTIAN L

ART UNIT	PAPER NUMBER
1652	

MAIL DATE	DELIVERY MODE
03/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

PTOL-90A (Rev. 10/06)

Response to Rule 312 Communication	Application No. 09/966,893	Applicant(s) D'AZZO ET AL.	
	Examiner Christian L. Fronda	Art Unit 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on <u>29 January 2007</u> under 37 CFR 1.312 has been considered, and has been:

 a) ☐ entered.

 b) ☐ entered as directed to matters of form not affecting the scope of the invention.

 c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

   Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

 d) ☒ disapproved. See explanation below.

 e) ☐ entered in part. See explanation below.

New claims 21-24 would be rejected under 112, 1st paragraph, for failing to comply with the enablment and written description requirements. The specification only provides enablement and a written description for a pharmaceutical composition that treats the diseases listed in claims 21 and 23 with the corresponding proteins listed in claims 22 and 24, respectively.

PONNATHAPU ACHUTAMURTHY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600